Recruiting
Early Phase 1

Glaucoma Eye Drop

Sponsor:

Johns Hopkins University

Code:

NCT07425535

Conditions

Glaucoma

Eligibility Criteria

Sex: All

Age: 30 - 70+

Healthy Volunteers: Accepted

Interventions

Latanoprost (0.005%)

Study Details

Brief summary:

Persons who do not have glaucoma will have pictures taken of the optic nerve with a standard camera before and 2 weeks after starting to take a daily glaucoma eye drop to lower eye pressure. These data will be used to compare to the same procedure performed with glaucoma patients to study how glaucoma injures the eye.

Conditions

Glaucoma

Study ID

NCT07425535

Start date

Jun 24, 2026

Status verified date

Jul, 2026

Completion date

Mar 31, 2028

Anticipated

Primary completion date

Mar 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 30 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Adults who have no history of OAG
  • Have an ocular examination by a glaucoma specialist with no indications of OAG
  • Have normal optical coherence tomography findings in the retinal nerve fiber layer.
  • Over age 30 will be included from
  • Both sexes
  • All ethnic groups.
  • Optic neuropathy.
  • Both suspects and those with glaucoma damage will be included.
  • When both eyes meet inclusion and exclusion criteria, both eyes will be included in the study and statistical methods will be used to account for correlations between eyes within the same individual.

Exclusion Criteria:

  • in whom sitting in an upright position is impossible due to physical disability
  • with ocular media opacity, corneal scarring, cataract or vitreous hemorrhage, that does not allow adequate imaging resolution.
  • in whom keeping the eyes open during the imaging procedure is not possible or uncomfortable.
  • who cannot perform home tonometry accurately at certification
  • who do not have reliable clinical Optical Coherence Tomography (OCT) testing.
  • with any form of glaucoma
  • with high myopia defined as refractive error > -8
  • with past keratorefractive surgery, corneal dystrophy, or corneal ectasia that would make self-tonometry measurements difficult to interpret
  • inability to understand English or with a language or hearing impairment

Study Design

Enrollment

30 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: Study group

The participants will take an approved glaucoma eye drop, latanoprost, for less than one month, with pictures of the eyes at baseline and while taking the drop.

Interventions

Latanoprost (0.005%)

Participants take the eye drop daily for less than one month

Primary outcome measure

  • Optic nerve head strain [ Time Frame: up to 1 month ]

Central Contacts and Locations

Central contacts

Harry A Quigley, MD

410 955 6051hquigley@jhmi.edu

Farzaneh Dadvar, MD

fdadvar1@jh.edu

Locations

Johns Hopkins Hospital

Recruiting

Baltimore, Maryland, United States, 21287

Contacts

Harry Quigley

443-742-7079hquigley@jhmi.edu

Farzaneh Dadvar

4103954535fdadvar1@jh.edu

Principal Investigator:

Harry A Quigley, MD

More Information

Sponsor

Johns Hopkins University

Last update posted

Jul 13, 2026

Last verified

Jul, 2026

Keywords

  • optic nerve
  • biomechanical strain
  • normal eye
  • glaucoma

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-27. This information was provided to ClinicalTrials.gov by Johns Hopkins University on 2026-07-13. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.